Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:53:49 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ESPR - ESPERION THERAPEUTICS INC - http://www.espr.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ESPR - Q1.01.88·1.920.81.90-0.09-4.54,197.87,5425,9892.01  2.01  1.883.40  0.7019:38:15Apr 2315 min RT 2¢

Recent Trades - Last 10 of 5989
Time ETExPriceChangeVolume
19:38:15Q1.90-0.09200
19:29:47Q1.90-0.09100
19:22:00Q1.90-0.09100
19:08:36Q1.9001-0.0899100
17:58:02Q1.91-0.083,400
17:53:16Q1.91-0.08900
17:34:08Q1.90-0.091,000
17:31:46Q1.90-0.091,000
17:31:04Q1.91-0.0810
17:21:41Q1.90-0.091,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-23 08:00U:ESPRNews ReleaseEsperion to Report First Quarter 2024 Financial Results on May 7
2024-04-07 14:45U:ESPRNews ReleaseEsperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL(TM) (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
2024-04-01 08:00U:ESPRNews ReleaseEsperion to Ring Nasdaq Opening Bell Today, April 1, 2024
2024-03-26 08:00U:ESPRNews ReleaseEsperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
2024-03-25 16:00U:ESPRNews ReleaseEsperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
2024-03-22 15:10U:ESPRNews ReleaseU.S. FDA Approves Broad New Labels for NEXLETOL(TM) and NEXLIZET(TM) to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
2024-03-22 11:05U:ESPRNews ReleaseCHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
2024-02-27 06:00U:ESPRNews ReleaseEsperion Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-16 16:30U:ESPRNews ReleaseEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-02-13 08:00U:ESPRNews ReleaseEsperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
2024-02-01 14:00U:ESPRNews ReleaseRFK, Esperion Therapeutics Announce 2024 Promotional Schedule
2024-01-23 16:00U:ESPRNews ReleaseEsperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters ¢ € ™ Option to Purchase Additional Shares
2024-01-18 21:16U:ESPRNews ReleaseEsperion Announces Pricing of $85.1 Million Public Offering of Common Stock
2024-01-18 16:00U:ESPRNews ReleaseEsperion Announces Proposed Public Offering of Common Stock
2024-01-03 07:00U:ESPRNews ReleaseEsperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
2023-12-18 08:00U:ESPRNews ReleaseEsperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
2023-12-13 16:00U:ESPRNews ReleaseU.S. FDA Updates LDL-C Lowering Indication for Esperion ¢ € ™s NEXLETOL ‚ ® (bempedoic acid) Tablet and NEXLIZET ‚ ® (bempedoic acid and ezetimibe) Tablet
2023-11-13 10:30U:ESPRNews ReleaseEsperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
2023-11-11 11:00U:ESPRNews ReleasePartners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
2023-11-09 16:30U:ESPRNews ReleaseEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)